E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration |
|
E.1.1.1 | Medical condition in easily understood language |
metastatic prostate cancer patients failing 1st line treatment with LHRH analogs or surgical castration |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 14.1 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10036909 |
E.1.2 | Term | Prostate cancer metastatic |
E.1.2 | System Organ Class | 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this randomized phase II open label trial is to determine the anti-tumor activity of TAK-700 (Orteronel) as compared to bicalutamide in terms of clinical progression-free survival in prostate cancer patients who failed 1st line treatment with LHRH (luteinizing hormone-releasing hormone) analogs or surgical castration.
|
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | Yes |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
1-Imaging sub-study
The goal of this sub-study is to compare the definition of progression by AS-MRI to the standard PCWG2 definition. Then the surrogacy of the new definition of the endpoint will be analyzed based on overall response to treatment.
AS-MRI sub-study will be investigated only for 1.5T scanners with the respective parameters as provided in the "Imaging guidelines".
2-Hormonal drivers project:
Collection of blood samples will be performed in this trial in order to further investigate hormonal drivers related to the drug's mechanism such as important enzyme (SNPs) and metabolites of the steroid biosynthesis pathway. |
|
E.3 | Principal inclusion criteria |
•Histologically confirmed diagnosis of prostate adenocarcinoma
•Metastatic disease in bone or other lesions documented by imaging. Abnormal 99mTc-bone scan imaging must be confirmed by Computed Tomography (CT) Scan or Magnetic resonance Imaging (MRI)
•Progressive disease following 1st line androgen deprivation therapy with LHRH (luteinizing hormone-releasing hormone) analogs or surgical castration. Recommendations of Prostate Cancer Working Group 2 (PCWG2)
•WHO (World health organization) performance status ≤ 2
•Life expectancy > 12 weeks
•Adequate bone marrow function (Absolute neutrophil count (ANC) 1500/μL; platelets 100,000/μL)
•Castrate serum levels of testosterone (< 50 ng/dL)
•Adequate renal function: calculated creatinine clearance > 40 mL/minute
•Adequate hepatic function:
◦Bilirubin: total bilirubin 1.5 Upper limit of Normal (ULN)
◦Asparate aminotransferase (AST) and/or Alanine aminotransferase (ALT) ≤ 2.5 x ULN in the absence of liver metastases or ≤ 5 x ULN if liver metastases are present
•Patients of reproductive potential should use adequate birth control measures, as defined by the investigator, during the study treatment period and for at least 4 months following the last study treatment. A highly effective method of birth control is defined as those that result in low failure rate (i.e. less than 1% per year) when used consistently and correctly
•Before patient registration/randomization, written informed consent must be given according to ICH/GCP (International conference on Harmonization-Good Clinical Practices), and national/local regulations
|
|
E.4 | Principal exclusion criteria |
•Cardiac function:
◦Screening calculated ejection fraction (Multi Gated Acquisition Scan (MUGA) scan, or by echocardiogram) must be ≥ 50%
◦No history of myocardial infarction, unstable symptomatic ischemic heart disease, ongoing arrhythmias of Grade > 2 thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, or symptomatic cerebrovascular events), or any other cardiac condition (e.g., pericardial effusion restrictive cardiomyopathy) within 6 months prior to first dose of study drug
◦Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed
◦Absence of New York Heart Association Class III or IV heart failure
◦Absence of Electrocardiogram (ECG) abnormalities of: Q-wave infarction, unless identified 6 or more months prior to screening and QTc interval > 470 msec
◦No uncontrolled hypertension despite appropriate medical therapy defined as blood pressure >160/90 mmHg at 2 separate measurements no more than 60 minutes apart during the Screening visit
•Prior radiotherapy but only for lymph nodes is allowed
•Prior or concomitant therapy:
◦No intake of narcotic analgesia for bone pain
◦No prior treatment with non-steroidal antiandrogens, within 6 months prior to randomization
◦No anticancer therapy or treatment with another investigational agent within the last 4 weeks prior to randomization
◦No prior therapy with TAK-700, ketoconazole, abiraterone, aminoglutethimide or MDV3100
◦Patients taking bisphosphonates or denosumab are eligible if they have received a stable dose for 4 weeks or more prior to randomization. (These treatments may then be continued on study)
•No known hypersensitivity to compounds related to TAK-700 or to TAK-700 excipients (refer to Investigator's brochure)
•No known gastrointestinal (GI) disease or GI procedure that could interfere with the GI absorption or tolerance of TAK-700, including difficulty swallowing tablets
•No prior history of adrenal insufficiency
•No prior history of malignancies other than prostate adenocarcinoma (except for basal cell or squamous cell carcinoma of the skin), or the patient has been free of malignancy for a period of 3 years prior to first dose of study drug
•No known active chronic hepatitis B or C, life-threatening illness unrelated to cancer, or any serious medical or psychiatric illness that could, in the investigator's opinion, potentially interfere with participation in this study
•No drug or alcohol abuse
•Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the trial is clinical progression free survival.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
the primary endpoint is counted from the day of randomization to the day of first diagnosis of clinical progression or the day of death of any cause that occurs prior or at the data analysis cut-off date. |
|
E.5.2 | Secondary end point(s) |
♦ RECIST 1.1 response in patients presenting with measurable disease
♦ Time to PSA progression and PSA change from baseline
♦ Overall survival
♦ Safety according to Common Terminology Criteria for Adverse Events, version 4.03
♦ Pain (when an SAE) or pain requiring initiation of narcotic analgesia
♦ Skeletal related events, including pathologic bone fractures (vertebral or non-vertebral), spinal cord compression, surgery to bone, focal radiation therapy to bone, a change of antineoplastic therapy to treat bone pain and hypercalcemia. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Time to PSA progression will be counted from the day of randomization to the day of first diagnosis of PSA progression. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 5 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 29 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
End of study occurs when all of the following criteria have been satisfied:
1. Thirty days after all patients have stopped protocol treatment.
2. The trial is mature for the analysis of the primary endpoint according to the conditions on number of events set in chapter 8.1.1.
3. The database has been fully cleaned and frozen for this analysis.
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |